Seneste nyheder

• 

  21 December 2023 00:00

  Almirall initiates first phase I clinical study of ALM223, an interleukin 2 mutant fusion protein for autoimmune diseases

  • The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223
  • ALM223 has the potential to rebalance the immune system in several autoimmune diseases (1,2)
  
  BARCELONA, Spain. 21st December, 2023 – Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study ev

• 

  12 December 2023 00:00

  Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology

  • The multi-target research and development partnership will focus on severe skin diseases
  • The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
  • In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial milestones as well as ti

• 

  14 November 2023 00:00

  Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

  The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases
  BARCELONA, Spain and VANCOUVER, (WA), USA. November 14th, 2023 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today

Kontakt

• 

  Christian Bruun-Andersen

  Pressekontakt General Manager, Nordics christian.bruun-andersen@almirall.com (+45) 31 62 83 53
• External communication team

  Pressekontakt Corporate Communications contact corporate.communication@almirall.com